TW200800983A - 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase - Google Patents

5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase

Info

Publication number
TW200800983A
TW200800983A TW095133237A TW95133237A TW200800983A TW 200800983 A TW200800983 A TW 200800983A TW 095133237 A TW095133237 A TW 095133237A TW 95133237 A TW95133237 A TW 95133237A TW 200800983 A TW200800983 A TW 200800983A
Authority
TW
Taiwan
Prior art keywords
inhibitors
pyrido
pyrimidines
dihydro
oxo
Prior art date
Application number
TW095133237A
Other languages
English (en)
Inventor
Mark R Player
Hui Huang
Huaping Hu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37665428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200800983(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TW200800983A publication Critical patent/TW200800983A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
TW095133237A 2005-09-14 2006-09-08 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase TW200800983A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71452605P 2005-09-14 2005-09-14
US79960506P 2006-05-10 2006-05-10

Publications (1)

Publication Number Publication Date
TW200800983A true TW200800983A (en) 2008-01-01

Family

ID=37665428

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095133237A TW200800983A (en) 2005-09-14 2006-09-08 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase

Country Status (10)

Country Link
US (1) US7728003B2 (zh)
EP (1) EP1945637A1 (zh)
JP (1) JP2009507920A (zh)
KR (1) KR20080046702A (zh)
AR (1) AR056510A1 (zh)
AU (1) AU2006291096A1 (zh)
BR (1) BRPI0616031A2 (zh)
CA (1) CA2622614A1 (zh)
TW (1) TW200800983A (zh)
WO (1) WO2007033137A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
CN101821266B (zh) 2007-09-14 2014-03-12 沃泰克斯药物股份有限公司 囊性纤维化跨膜通道调节因子的调节剂
WO2010131170A1 (en) 2009-05-14 2010-11-18 Koninklijke Philips Electronics N.V. Lighting arrangement
EP3307741B1 (de) * 2015-06-09 2020-10-28 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
CN111848613B (zh) * 2020-08-11 2021-09-24 山东大学 一种二芳基嘧啶骈吡啶酮类衍生物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903850A1 (de) 1979-02-01 1980-08-07 Bayer Ag 2-amino-8-cyclopropyl-5-oxo-5,8- dihydro-pyrido eckige klammer auf 2,3-d eckige klammer zu -pyrimidin-6-carnonsaeuren, verfahren zu ihrer herstellung sowie ihrer verwendung als antibakterielle mittel
PL181867B1 (pl) 1994-06-14 2001-09-28 Dainippon Pharmaceutical Co Nowe zwiazki, sposoby ich wytwarzania i srodki przeciw nowotworowe PL
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
CA2225555A1 (en) * 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use
JP4323574B2 (ja) 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
BR9811956B1 (pt) 1997-08-20 2010-06-01 naftiridinonas e composição farmacêutica compreendendo as mesmas.
DK1268481T3 (da) * 1999-09-17 2008-05-05 Abbott Gmbh & Co Kg Inaseinkibitorer som terapeutiske midler
NZ520962A (en) 2000-03-06 2003-09-26 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors
CA2533626A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
AU2006291007A1 (en) 2005-09-14 2007-03-22 Janssen Pharmaceutica, N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase

Also Published As

Publication number Publication date
US20070060578A1 (en) 2007-03-15
WO2007033137A1 (en) 2007-03-22
EP1945637A1 (en) 2008-07-23
KR20080046702A (ko) 2008-05-27
AU2006291096A1 (en) 2007-03-22
CA2622614A1 (en) 2007-03-22
AR056510A1 (es) 2007-10-10
JP2009507920A (ja) 2009-02-26
BRPI0616031A2 (pt) 2011-06-07
US7728003B2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
WO2008055013A3 (en) 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
WO2007023382A3 (en) Pyrimidine amino pyrazole compounds, potent kinase inhibitors
UA93375C2 (ru) Ингибиторы протеинкиназ ha ochobe замещенных амидов
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
WO2007072153A3 (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
TW200833675A (en) Nicotinamide derivatives
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
UA99311C2 (en) Inhibitors of c-fms kinase
SE0400284D0 (sv) Novel compounds
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
MXPA05010875A (es) Derivados de piperazina como inhibidores de renina.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
GB0308201D0 (en) Novel compounds
PL1877364T3 (pl) Pochodne fenyloacetylenu o powinowactwie do receptora mGluR5
TW200628153A (en) Novel compounds
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
WO2007000340A8 (en) Bicyclic derivatives as p38 kinase inhibitors
WO2007017728A3 (en) Novel heterocyclic compounds
TW200800983A (en) 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
GB0513886D0 (en) Novel compounds
WO2007000337A8 (en) Bicyclic derivatives as p38 kinase inhibitors
MX2009004625A (es) Derivados de 3-amino-pirazol-4-carboxamida utiles como inhibidores de proteina cinasas.